Innovations in Cardiac Implantable Electronic Devices

Khan, Khurrum; Kim, Jitae A; Gurgu, Andra; Khawaja, Muzamil; Cozma, D.; Chelu, Mihail G.

doi:10.1007/s10557-021-07163-5

Cited by 14 publications

(6 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CIEDs can be divided into two categories: (I) pacemakers for bradycardia and (II) ICDs for defibrillation of tachycardia. Devices that do not require a transvenous lead have been developed ( 6 ). Cardiac resynchronization therapy (CRT) is also included in CIEDs with transvenous leads, but the potential issues that are associated with CRT are discussed below.…”

Section: Device Therapy For Patients With Svc Obstructionmentioning

confidence: 99%

Superior vena cava obstruction and cardiovascular implantable electronic devices—a new era of leadless devices

Kabutoya

2024

Mediastinum

View full text Add to dashboard Cite

Cardiovascular implantable electronic devices (CIEDs) such as pacemakers and implantable cardioverter defibrillators require the placement of a transvenous lead through the superior vena cava (SVC), which can be difficult if there is stenosis or obstruction of the SVC. Moreover, SVC syndrome may occur after the lead is inserted even if the SVC was intact before the implantation. Therefore, there is need of an appropriate strategy for handling stenosis or obstruction of SVC during lead placement. In addition, advances are being made in CIEDs that do not require transvenous leads, and thus CIEDs without a transvenous lead should be considered depending on the indications and urgency of the particular case. This manuscript is divided into (I) device therapy for patients with SVC obstruction and (II) therapeutic strategy for SVC obstruction after lead implantation. In patients with SVC syndrome, treatment of the SVC occlusion should be based on the individual pathophysiology, and depending on the indications and urgency of the case, treatment with CIEDs that do not require transvenous leads should be considered. Further data must be accumulated to clarify the long-term prognosis of device implantation after treatment of SVC occlusion. In addition, transvenous lead extraction is now widely used for device-related SVC obstruction, and this procedure also merits further accumulation of data.

show abstract

Section: Device Therapy For Patients With Svc Obstructionmentioning

confidence: 99%

Superior vena cava obstruction and cardiovascular implantable electronic devices—a new era of leadless devices

Kabutoya

2024

Mediastinum

View full text Add to dashboard Cite

show abstract

“…While there are several types of Cardiac Implantable Electronic Devices (CIEDs), the three most common are pacemakers, implantable cardioverter-de brillators (ICDs), and cardiac resynchronization therapy (CRT). These devices treat various cardiac conditions, including tachyarrhythmias, bradyarrhythmias, and medically refractory heart failure (HF) (4,5).…”

Section: Objectivementioning

confidence: 99%

Cohort Profile: Iranian Electronic Physiology Registry (IEPR)

Nikoo,

Jorat,

Heydari

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective: Cardiac Implantable Electronic Devices have emerged as an important treatment modality in the field of electrophysiology. The use of cardiac devices including pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT), has increased significantly over the past few decades. The long-term outcomes of these devices need to be investigated. Data description: The Iranian Electronic Physiology Registry (IEPR) will identify factors that may predispose patients to complications, long-term outcomes of cardiac devices, hospitalizations, and mortality rates.

show abstract

“…Cardiac contractile force modulation (CCM) is an electrical device therapy in which non‐activating electrical pulses are applied to the myocardium during the absolute refractory period, and has been proposed as a treatment option for patients with chronic heart failure (HF) with reduced left ventricular ejection fraction (LVEF), which can enhance exercise tolerance and reduce cardiovascular mortality and hospitalization for HF 1 . Indications for CCM include patients with reduced LVEF, normal or slightly longer duration of QRS, and who do not meet the criteria for cardiac resynchronization therapy 2 . Since many patients undergoing CCM have an LVEF of 35% or less, guideline recommendations should be considered with prophylactic placement of an implantable cardioverter defibrillator 3 .…”

Section: Introductionmentioning

confidence: 99%

“…1 Indications for CCM include patients with reduced LVEF, normal or slightly longer duration of QRS, and who do not meet the criteria for cardiac resynchronization therapy. 2 Since many patients undergoing CCM have an LVEF of 35% or less, guideline recommendations should be considered with prophylactic placement of an implantable cardioverter defibrillator. 3 According to the guideline, the subcutaneous implantable cardioverter-defibrillator Abbreviations: BNP, brain natriuretic peptide; CCM, cardiac contractility modulation; ECG, electrocardiogram; HF, heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; S-ICD, subcutaneous implantable cardioverter-defibrillator; VF, ventricular fibrillation.…”

Section: Introductionmentioning

confidence: 99%

Cardiac contractility modulation and subcutaneous defibrillator (S‐ICD): First experience with simultaneous implantation

Yao

Gao

Yan

et al. 2023

Pacing Clinical Electrophis

View full text Add to dashboard Cite

BackgroundsTwo technologies, cardiac contractility modulation (CCM) and subcutaneous implantable cardioverter‐defibrillator (S‐ICD), can be successfully combined and applied to patients with advanced heart failure (HF) with reduced left ventricular ejection fraction (LVEF).Case ReportWe reported a case of a 51‐year‐old man with reduced ejection fraction (LVEF = 33%) and a narrow QRS complex who first underwent simultaneous implantation of CCM and S‐ICD.ConclusionOur case report aimed to reveal that the simultaneous implantation of CCM and S‐ICD could be successfully used in patients with advanced HF, which could significantly improve the clinical symptoms of such patients during one surgery.

show abstract

Innovations in Cardiac Implantable Electronic Devices

Cited by 14 publications

References 102 publications

Superior vena cava obstruction and cardiovascular implantable electronic devices—a new era of leadless devices

Superior vena cava obstruction and cardiovascular implantable electronic devices—a new era of leadless devices

Cohort Profile: Iranian Electronic Physiology Registry (IEPR)

Cardiac contractility modulation and subcutaneous defibrillator (S‐ICD): First experience with simultaneous implantation

Contact Info

Product

Resources

About